Equillium : Corporate Overview - September 2021

Corporate Presentation

September 2021

Forward-Looking Statements

This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "objective," "believe," "estimate," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on Company management's current beliefs and expectations. These statements include but are not limited to statements regarding the Company's business strategy, the Company's plans to develop and commercialize its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, size and growth potential of the markets for the Company's product candidates and cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements.

Actual results or events could differ materially from the plans, intentions and expectations disclosed or implied in the forward-looking statements the Company makes due to the risks and uncertainties inherent in the Company's business, including without limitation, risk described in the Company's filings with the Securities and Exchange Commission ("SEC"). You are cautioned not to place undue reliance on these forward-looking statements, which represent the Company's views as of the date of this presentation. The Company's anticipates that subsequent events and developments will cause the its views to change. However, while the Company may elect to update these forward- looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in the Company's filings and reports, which may be accessed for free by visiting EDGAR on the SEC web site at http://www.sec.gov and on the Company's website under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the "safe harbor" provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

2

Equillium Snapshot

Leaders in Novel	Validated	Strategic Partnership
CD6 Biology	Therapeutic	with Biocon Limited
• Itolizumab - the first-in-class	• Itolizumab has received EUA for	• Commercial rights to U.S., Canada,
antibody targeting the CD6-ALCAM	CRS/ARDS in COVID-19 and	Australia, & New Zealand
pathway	approval for Psoriasis in India	• Commercial-scale manufacturing
• Highly differentiated MoA, inhibiting		and supply agreement
both activity and trafficking of
T effector cells

Strong Cash Balance	First-Line aGVHD
• $97.6M at end of Q2 2021	• Pivotal Phase 3 study to support BLA
• Well capitalized to reach	• Study initiation planned Q4 2021
near-term catalysts	• Potential to be first to market
	in aGVHD first-line treatment

Proof-of-Concept

• PoC studies for SLE/LN and uncontrolled asthma ongoing, data anticipated 2H 2021

3

Accomplished Management Team

Bruce Steel, CFA

CHIEF EXECUTIVE OFFICER

BioMed Ventures • Rincon

Anaphore • Ambit

Christine

Zedelmayer

CHIEF OPERATING OFFICER

Amylin • Amgen • Ligand

Extensive Industry Experience

Dolca Thomas, MD

EVP RESEARCH & DEVELOPMENT CHIEF MEDICAL OFFICER

Principia • Roche • Pfizer Bristol Meyers Squibb

Jason Keyes

CHIEF FINANCIAL OFFICER

Orexigen • Amylin

Amgen • Baxter

Steve Connelly, PHD

CHIEF SCIENTIFIC OFFICER

BioMed Ventures • aTyr Pharma The Scripps Research Institute

Joel Rothman

CHIEF DEVELOPMENT OFFICER

Cytokinetics • Genentech Raptor • Jazz Pharmaceuticals

Rincon

Pharmaceuticals

4

Itolizumab: Pipeline-in-a-Product

Indication Selection Strategy

Strong scientific rationale

T Cell Mediated Immuno-inflammatory Diseases

	Acute Graft-Versus-
Solid Organ	Host Disease
Rejection	Chronic GVHD /
	GVHD Prev ention
Multiple Sclerosis	Crohn's Disease

Robust preclinical / translational data

High unmet medical need

Compelling commercial opportunity

Neuromyelitis

Optica

Uncontrolled Asthma

Interstitial Lung

Diseases

Atopic Dermatitis

Psoriasis

Current clinical

dev elopment programs

Ulcerativ e Colitis

	Lupus/Lupus Nephritis
	Vasculitis
	Scleroderma
	Behcet's Disease
	Rheumatoid Arthritis
	Psoriatic Arthritis
Uv eitis
Research Implicates CD6/ALCAM	T cell mediated diseases
pathw ay in disease pathogenesis
5